1. Home
  2. GFR vs RIGL Comparison

GFR vs RIGL Comparison

Compare GFR & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GFR
  • RIGL
  • Stock Information
  • Founded
  • GFR 2018
  • RIGL 1996
  • Country
  • GFR Canada
  • RIGL United States
  • Employees
  • GFR N/A
  • RIGL N/A
  • Industry
  • GFR
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • GFR
  • RIGL Health Care
  • Exchange
  • GFR Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • GFR 318.9M
  • RIGL 335.5M
  • IPO Year
  • GFR N/A
  • RIGL 2000
  • Fundamental
  • Price
  • GFR $5.25
  • RIGL $38.85
  • Analyst Decision
  • GFR
  • RIGL Buy
  • Analyst Count
  • GFR 0
  • RIGL 5
  • Target Price
  • GFR N/A
  • RIGL $38.20
  • AVG Volume (30 Days)
  • GFR 42.0K
  • RIGL 995.6K
  • Earning Date
  • GFR 08-06-2025
  • RIGL 08-05-2025
  • Dividend Yield
  • GFR N/A
  • RIGL N/A
  • EPS Growth
  • GFR N/A
  • RIGL N/A
  • EPS
  • GFR 2.05
  • RIGL 5.43
  • Revenue
  • GFR $516,308,125.00
  • RIGL $267,921,000.00
  • Revenue This Year
  • GFR N/A
  • RIGL $59.93
  • Revenue Next Year
  • GFR $27.03
  • RIGL N/A
  • P/E Ratio
  • GFR $2.52
  • RIGL $7.15
  • Revenue Growth
  • GFR N/A
  • RIGL 105.62
  • 52 Week Low
  • GFR $3.81
  • RIGL $12.66
  • 52 Week High
  • GFR $8.16
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • GFR 67.48
  • RIGL 68.57
  • Support Level
  • GFR $4.14
  • RIGL $39.00
  • Resistance Level
  • GFR $5.01
  • RIGL $42.08
  • Average True Range (ATR)
  • GFR 0.25
  • RIGL 2.32
  • MACD
  • GFR 0.07
  • RIGL -0.37
  • Stochastic Oscillator
  • GFR 97.96
  • RIGL 53.26

About GFR Greenfire Resources Ltd.

Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: